Biopharma (Operating Segment) was the largest of Sanofi’s 2 reported lines in fiscal 2024, at $123.24B — 50% of $246.49B.
| Segment | FY 2015 | FY 2016 | FY 2017 | FY 2020 | FY 2024 |
|---|---|---|---|---|---|
| Biopharma (Operating Segment) | $123.24B | ||||
| Reportable Segments | $123.24B | ||||
| Pharmaceuticals | — | ||||
| Vaccines | — | ||||
| Consumer Healthcare Segment | — | ||||
| Total | $246.49B |
In fiscal 2024, which ended December 31, 2024, the 2 segments Sanofi reported in this breakdown added up to $246.49B. Biopharma (Operating Segment) was the largest segment, at $123.24B or 50.0% of the total, followed by Reportable Segments ($123.24B, 50.0%).
The table also keeps 3 segments that Sanofi no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers 5 fiscal years between 2015 and 2024, as reported in Sanofi's annual filings.
Previously Stated was the largest of Sanofi’s 3 reported lines in fiscal 2016, at $101.46B — 100% of $101.39B.
| Retrospective application and retrospective restatement [axis] | FY 2016 |
|---|---|
| Previously Stated | $101.46B |
| Impact Of Ifrs15 | -$36.00M |
| Increase (Decrease) Due To Application Of Ifrs 15 | -$36.00M |
| Total | $101.39B |
In fiscal 2016, which ended December 31, 2016, the 3 revenue lines Sanofi reported in this breakdown added up to $101.39B. Previously Stated was the largest revenue line, at $101.46B or 100.1% of the total.
Figures are shown as reported, so the total is net of Impact Of Ifrs15, which was -$36.00M in fiscal 2016. This breakdown covers every fiscal year from 2016 to 2016, as reported in Sanofi's annual filings.
Sanofi (SNY) breaks its revenue down by segment and revenue line. In fiscal 2024, its largest segment was Biopharma (Operating Segment), with $123.24B or 50.0% of the total, followed by Reportable Segments at $123.24B (50.0%).
Biopharma (Operating Segment) was Sanofi's largest segment in fiscal 2024, with $123.24B in revenue, 50.0% of the $246.49B reported across its 2 segments.
Previously Stated was Sanofi's largest revenue line in fiscal 2016, with $101.46B in revenue, 100.1% of the $101.39B reported across its 3 revenue lines.
Every figure is taken from Sanofi's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2015 to 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.